Damora Therapeutics, Inc. (DMRA) - Total Liabilities
Based on the latest financial reports, Damora Therapeutics, Inc. (DMRA) has total liabilities worth $20.15 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. For the complete balance sheet picture, see Damora Therapeutics, Inc. total assets.
Damora Therapeutics, Inc. - Total Liabilities Trend (2018–2025)
This chart illustrates how Damora Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore DMRA long-term asset investment ratio to see how much of total assets are deployed in long-term investments.
Damora Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Damora Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Uniqure NV
NASDAQ:QURE
|
USA | $659.64 Million |
|
Sunvim Group Co Ltd
SHE:002083
|
China | CN¥2.93 Billion |
|
Dalian Huarui Heavy Industry Group Co Ltd
SHE:002204
|
China | CN¥19.40 Billion |
|
Telkom
JSE:TKG
|
South Africa | ZAC28.53 Billion |
|
GigaCloud Technology Inc Class A Ordinary Shares
NASDAQ:GCT
|
USA | $716.66 Million |
|
NCAB Group
ST:NCAB
|
Sweden | Skr2.08 Billion |
|
Xeris Pharmaceuticals Inc
NASDAQ:XERS
|
USA | $421.64 Million |
|
PROG Holdings Inc
NYSE:PRG
|
USA | $1.27 Billion |
Liability Composition Analysis (2018–2025)
This chart breaks down Damora Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. Check Damora Therapeutics, Inc. (DMRA) asset resilience to evaluate the company's liquid asset resilience ratio.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 12.98 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.08 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.08 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Damora Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Damora Therapeutics, Inc. (2018–2025)
The table below shows the annual total liabilities of Damora Therapeutics, Inc. from 2018 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $20.15 Million | +657.12% |
| 2024-12-31 | $2.66 Million | -54.87% |
| 2023-12-31 | $5.90 Million | -48.44% |
| 2022-12-31 | $11.44 Million | +129.07% |
| 2021-12-31 | $4.99 Million | -18.26% |
| 2020-12-31 | $6.11 Million | -24.96% |
| 2019-12-31 | $8.14 Million | +83.12% |
| 2018-12-31 | $4.44 Million | -- |
About Damora Therapeutics, Inc.
Damora Therapeutics, Inc., a biopharmaceutical company, develops therapies for the treatment of hematologic disorders in Denmark and North America. The company's lead product includes DMR-001, a investigational monoclonal antibody therapy that targets mutations in CALR, for the treatment of essential thrombocythemia; and DMR-002 and DMR-003, both anti-mutCALR-based therapies, with the intent to u… Read more